THE 60-SECOND GUIDE
Cagrilintide
Investigational · human trials incomplete.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Cagrilintide is a long-acting amylin analog being studied for weight management. It has been tested alone and with semaglutide; evidence for the combination CagriSema belongs to a separate treatment record. [1]
Potential benefits
Long-acting amylin analog studied for weight management. Investigated alone and in combination with semaglutide. [1]
Evidence & its limits
The 2021 component trial measured bodyweight, safety, and tolerability; gastrointestinal and administration-site reactions were common. Results from CagriSema cannot be assigned entirely to cagrilintide or used to validate independently mixed products. Cagrilintide remains investigational. [1]
Risks & unknowns
Not FDA-approved. Combination benefits, adverse effects, and long-term outcomes remain under study. [1]
Status & scope
Not FDA-approved. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- Randomized phase II dose-finding trial, 2021
- Cagrilintide with semaglutide phase 1b trial, 2021
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.